Index
1 Market Overview
1.1 Product Overview and Scope of Blood Cancer Molecular Diagnostics
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Blood Cancer Molecular Diagnostics by Type
1.3.1 Overview: Global Blood Cancer Molecular Diagnostics Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global Blood Cancer Molecular Diagnostics Consumption Value Market Share by Type in 2022
1.3.3 Polymerase Chain Reaction
1.3.4 Molecular Hybridization
1.3.5 Biochip
1.3.6 Others
1.4 Global Blood Cancer Molecular Diagnostics Market by Application
1.4.1 Overview: Global Blood Cancer Molecular Diagnostics Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Hospital
1.4.3 Third-Party Testing Agency
1.4.4 Others
1.5 Global Blood Cancer Molecular Diagnostics Market Size & Forecast
1.6 Global Blood Cancer Molecular Diagnostics Market Size and Forecast by Region
1.6.1 Global Blood Cancer Molecular Diagnostics Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Blood Cancer Molecular Diagnostics Market Size by Region, (2018-2029)
1.6.3 North America Blood Cancer Molecular Diagnostics Market Size and Prospect (2018-2029)
1.6.4 Europe Blood Cancer Molecular Diagnostics Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Blood Cancer Molecular Diagnostics Market Size and Prospect (2018-2029)
1.6.6 South America Blood Cancer Molecular Diagnostics Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Blood Cancer Molecular Diagnostics Market Size and Prospect (2018-2029)
2 Company Profiles
2.1 Roche Diagnostics
2.1.1 Roche Diagnostics Details
2.1.2 Roche Diagnostics Major Business
2.1.3 Roche Diagnostics Blood Cancer Molecular Diagnostics Product and Solutions
2.1.4 Roche Diagnostics Blood Cancer Molecular Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Roche Diagnostics Recent Developments and Future Plans
2.2 Abbott
2.2.1 Abbott Details
2.2.2 Abbott Major Business
2.2.3 Abbott Blood Cancer Molecular Diagnostics Product and Solutions
2.2.4 Abbott Blood Cancer Molecular Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Abbott Recent Developments and Future Plans
2.3 Thermo Fisher
2.3.1 Thermo Fisher Details
2.3.2 Thermo Fisher Major Business
2.3.3 Thermo Fisher Blood Cancer Molecular Diagnostics Product and Solutions
2.3.4 Thermo Fisher Blood Cancer Molecular Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Thermo Fisher Recent Developments and Future Plans
2.4 Qiagen
2.4.1 Qiagen Details
2.4.2 Qiagen Major Business
2.4.3 Qiagen Blood Cancer Molecular Diagnostics Product and Solutions
2.4.4 Qiagen Blood Cancer Molecular Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Qiagen Recent Developments and Future Plans
2.5 Illumina
2.5.1 Illumina Details
2.5.2 Illumina Major Business
2.5.3 Illumina Blood Cancer Molecular Diagnostics Product and Solutions
2.5.4 Illumina Blood Cancer Molecular Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Illumina Recent Developments and Future Plans
2.6 Agilent
2.6.1 Agilent Details
2.6.2 Agilent Major Business
2.6.3 Agilent Blood Cancer Molecular Diagnostics Product and Solutions
2.6.4 Agilent Blood Cancer Molecular Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Agilent Recent Developments and Future Plans
2.7 Liferiver
2.7.1 Liferiver Details
2.7.2 Liferiver Major Business
2.7.3 Liferiver Blood Cancer Molecular Diagnostics Product and Solutions
2.7.4 Liferiver Blood Cancer Molecular Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Liferiver Recent Developments and Future Plans
2.8 Gpmedical
2.8.1 Gpmedical Details
2.8.2 Gpmedical Major Business
2.8.3 Gpmedical Blood Cancer Molecular Diagnostics Product and Solutions
2.8.4 Gpmedical Blood Cancer Molecular Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Gpmedical Recent Developments and Future Plans
2.9 Zeesan
2.9.1 Zeesan Details
2.9.2 Zeesan Major Business
2.9.3 Zeesan Blood Cancer Molecular Diagnostics Product and Solutions
2.9.4 Zeesan Blood Cancer Molecular Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Zeesan Recent Developments and Future Plans
2.10 Berry Oncology
2.10.1 Berry Oncology Details
2.10.2 Berry Oncology Major Business
2.10.3 Berry Oncology Blood Cancer Molecular Diagnostics Product and Solutions
2.10.4 Berry Oncology Blood Cancer Molecular Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Berry Oncology Recent Developments and Future Plans
2.11 Annoroad
2.11.1 Annoroad Details
2.11.2 Annoroad Major Business
2.11.3 Annoroad Blood Cancer Molecular Diagnostics Product and Solutions
2.11.4 Annoroad Blood Cancer Molecular Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Annoroad Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Blood Cancer Molecular Diagnostics Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Blood Cancer Molecular Diagnostics by Company Revenue
3.2.2 Top 3 Blood Cancer Molecular Diagnostics Players Market Share in 2022
3.2.3 Top 6 Blood Cancer Molecular Diagnostics Players Market Share in 2022
3.3 Blood Cancer Molecular Diagnostics Market: Overall Company Footprint Analysis
3.3.1 Blood Cancer Molecular Diagnostics Market: Region Footprint
3.3.2 Blood Cancer Molecular Diagnostics Market: Company Product Type Footprint
3.3.3 Blood Cancer Molecular Diagnostics Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 Market Size Segment by Type
4.1 Global Blood Cancer Molecular Diagnostics Consumption Value and Market Share by Type (2018-2023)
4.2 Global Blood Cancer Molecular Diagnostics Market Forecast by Type (2024-2029)
5 Market Size Segment by Application
5.1 Global Blood Cancer Molecular Diagnostics Consumption Value Market Share by Application (2018-2023)
5.2 Global Blood Cancer Molecular Diagnostics Market Forecast by Application (2024-2029)
6 North America
6.1 North America Blood Cancer Molecular Diagnostics Consumption Value by Type (2018-2029)
6.2 North America Blood Cancer Molecular Diagnostics Consumption Value by Application (2018-2029)
6.3 North America Blood Cancer Molecular Diagnostics Market Size by Country
6.3.1 North America Blood Cancer Molecular Diagnostics Consumption Value by Country (2018-2029)
6.3.2 United States Blood Cancer Molecular Diagnostics Market Size and Forecast (2018-2029)
6.3.3 Canada Blood Cancer Molecular Diagnostics Market Size and Forecast (2018-2029)
6.3.4 Mexico Blood Cancer Molecular Diagnostics Market Size and Forecast (2018-2029)
7 Europe
7.1 Europe Blood Cancer Molecular Diagnostics Consumption Value by Type (2018-2029)
7.2 Europe Blood Cancer Molecular Diagnostics Consumption Value by Application (2018-2029)
7.3 Europe Blood Cancer Molecular Diagnostics Market Size by Country
7.3.1 Europe Blood Cancer Molecular Diagnostics Consumption Value by Country (2018-2029)
7.3.2 Germany Blood Cancer Molecular Diagnostics Market Size and Forecast (2018-2029)
7.3.3 France Blood Cancer Molecular Diagnostics Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Blood Cancer Molecular Diagnostics Market Size and Forecast (2018-2029)
7.3.5 Russia Blood Cancer Molecular Diagnostics Market Size and Forecast (2018-2029)
7.3.6 Italy Blood Cancer Molecular Diagnostics Market Size and Forecast (2018-2029)
8 Asia-Pacific
8.1 Asia-Pacific Blood Cancer Molecular Diagnostics Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Blood Cancer Molecular Diagnostics Consumption Value by Application (2018-2029)
8.3 Asia-Pacific Blood Cancer Molecular Diagnostics Market Size by Region
8.3.1 Asia-Pacific Blood Cancer Molecular Diagnostics Consumption Value by Region (2018-2029)
8.3.2 China Blood Cancer Molecular Diagnostics Market Size and Forecast (2018-2029)
8.3.3 Japan Blood Cancer Molecular Diagnostics Market Size and Forecast (2018-2029)
8.3.4 South Korea Blood Cancer Molecular Diagnostics Market Size and Forecast (2018-2029)
8.3.5 India Blood Cancer Molecular Diagnostics Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Blood Cancer Molecular Diagnostics Market Size and Forecast (2018-2029)
8.3.7 Australia Blood Cancer Molecular Diagnostics Market Size and Forecast (2018-2029)
9 South America
9.1 South America Blood Cancer Molecular Diagnostics Consumption Value by Type (2018-2029)
9.2 South America Blood Cancer Molecular Diagnostics Consumption Value by Application (2018-2029)
9.3 South America Blood Cancer Molecular Diagnostics Market Size by Country
9.3.1 South America Blood Cancer Molecular Diagnostics Consumption Value by Country (2018-2029)
9.3.2 Brazil Blood Cancer Molecular Diagnostics Market Size and Forecast (2018-2029)
9.3.3 Argentina Blood Cancer Molecular Diagnostics Market Size and Forecast (2018-2029)
10 Middle East & Africa
10.1 Middle East & Africa Blood Cancer Molecular Diagnostics Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Blood Cancer Molecular Diagnostics Consumption Value by Application (2018-2029)
10.3 Middle East & Africa Blood Cancer Molecular Diagnostics Market Size by Country
10.3.1 Middle East & Africa Blood Cancer Molecular Diagnostics Consumption Value by Country (2018-2029)
10.3.2 Turkey Blood Cancer Molecular Diagnostics Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Blood Cancer Molecular Diagnostics Market Size and Forecast (2018-2029)
10.3.4 UAE Blood Cancer Molecular Diagnostics Market Size and Forecast (2018-2029)
11 Market Dynamics
11.1 Blood Cancer Molecular Diagnostics Market Drivers
11.2 Blood Cancer Molecular Diagnostics Market Restraints
11.3 Blood Cancer Molecular Diagnostics Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
11.5 Influence of COVID-19 and Russia-Ukraine War
11.5.1 Influence of COVID-19
11.5.2 Influence of Russia-Ukraine War
12 Industry Chain Analysis
12.1 Blood Cancer Molecular Diagnostics Industry Chain
12.2 Blood Cancer Molecular Diagnostics Upstream Analysis
12.3 Blood Cancer Molecular Diagnostics Midstream Analysis
12.4 Blood Cancer Molecular Diagnostics Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer